The safety of patients remains our highest priority and since our NDA submission no new safety signals have been observed to date in our ongoing TransCon PTH Phase 2 and Phase 3 clinical trials or in our Expanded Access Program EAP  program and these programs continue unchanged  Knowing the serious unmet medical need that patients with hypoparathyroidism face we will continue to make TransCon PTH available to patients participating in these ongoing clinical trials  as well as to physicians through our US EAP which remains open for enroll ment for eligible adult patients previously treated with parathyroid hormone  continued Mikkelsen